AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Dr. Christoph Klade, Chief Scientific Officer
Phone: +43 503 72 44-24
  • PROUD-PV study results
  • polycythemia vera
  • Ropeginterferon
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (6 releases)

* High rates and durable Clinical and Hematological response were achieved with Ropeginterferon alfa-2b at 24 months of treatment [more]

AOP Orphan announces two-year results on Ropeginterferon alfa-2bin PV
2017-12-10, pts20171210001 Health/Medicine, Science/Technology
AOP Orphan Pharmaceuticals AG to acquire Selisistat
2017-10-02, pts20171002022 Products/Innovations, Health/Medicine
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations